Fresh off the research radar — new HBOT science just published, summarized for our community.
Title:
Scoping review finds HBOT improves insulin sensitivity, lowers fasting glucose, and reduces inflammation — with effects beginning after the first treatment
What this review examined
Insulin resistance is the core driver behind:
- type 2 diabetes
- metabolic syndrome
- weight gain
- chronic inflammation
- cardiovascular disease
It develops long before diabetes is diagnosed, making it one of the most important early targets for intervention.
Because diabetes is one of the most common conditions seen in patients undergoing HBOT, clinicians have long noticed metabolic improvements — but until now, no review had organized the data.
This 2025 scoping review examined all available evidence on how HBOT affects insulin resistance.
What was included
- 230 studies screened
- 17 eligible studies
- Included human and animal data
- Focused specifically on insulin, insulin resistance and insulin sensitivity
- Excluded normobaric oxygen and non-English/Spanish/Portuguese articles
Key findings
1. HBOT improves fasting glucose
Multiple studies showed lower fasting glycaemia after HBOT.
2. HBOT decreases insulin resistance
Consistent across studies:
- increased insulin sensitivity
- reduced markers of insulin resistance
This was seen in both diabetic and non-diabetic groups.
3. Effects begin after a single HBOT session
One of the most striking findings:
Measurable metabolic improvements appeared after just one HBOT session.
This suggests a strong physiological effect that begins immediately.
4. HBOT reduces pro-inflammatory cytokines
Chronic inflammation is a major cause of insulin resistance.
HBOT lowered inflammatory mediators linked to:
- impaired insulin signaling
- mitochondrial dysfunction
- metabolic rigidity
5. Mechanisms likely involve mitochondrial efficiency + oxygen-dependent pathways
Although the exact molecular pathways remain unclear, the review highlights oxygen’s role in:
- boosting mitochondrial ATP production
- reducing hypoxia-driven inflammation
- improving GLUT4 glucose transporter function
- increasing tissue oxygenation in insulin-resistant cells
6. Duration of improvement remains unknown
The review notes that we do not yet know:
- how long insulin sensitivity stays improved
- whether a full HBOT protocol leads to long-term metabolic changes
More research is needed.
Why this matters
This review reinforces a growing body of evidence:
HBOT is not just for wounds and neurological issues — it is a metabolic therapy.
Insulin resistance is one of the most damaging early metabolic shifts in the modern world.
If HBOT can:
- improve insulin sensitivity
- reduce inflammation
- lower fasting glucose
- quickly shift metabolic function
…it has enormous implications for:
- prediabetes
- metabolic syndrome
- PCOS
- long COVID-related metabolic dysfunction
- obesity driven by insulin resistance
- mitochondrial disorders
Many people with chronic illnesses have hidden insulin resistance even if they are not overweight — this makes HBOT a potential early intervention tool.
Takeaway for the community
This 2025 scoping review shows that:
- HBOT improves fasting glucose
- HBOT enhances insulin sensitivity
- effects begin after the first session
- inflammation related to insulin resistance decreases
- HBOT may be a meaningful tool for preventing or reversing early metabolic dysfunction
However, the authors emphasize the need for large, rigorous randomized trials before HBOT can be widely recommended for insulin resistance in clinical guidelines.
Study link: https://pubmed.ncbi.nlm.nih.gov/41322229/
HBOT Radar continues to follow new research on HBOT’s metabolic effects, including glucose regulation, mitochondrial function and long-term insulin sensitivity.
